Available option
CJC-1295 (No DAC) 5mg + Ipamorelin 5mg / 1.2mL
10mg totalStaff-prepared solution
- Composition
- CJC-1295 (No DAC) 5mg + Ipamorelin 5mg / 1.2mL
- Format
- Staff-prepared solution
Bear Biotech catalogue
CJC-1295 (No DAC) + Ipamorelin
Combined GHRH and growth-hormone-secretagogue research materials
- GHRH signalling
- GHS receptor
- Blend evidence limits
Available presentations
Choose a strength and format
Each available presentation is listed separately. Current prices are confirmed from the Bear Biotech catalogue.
Research overview
What is CJC-1295 (No DAC) + Ipamorelin?
This pairing is used in research because the two components approach growth-hormone signalling through different receptors: a short-acting GHRH analogue and a ghrelin-receptor agonist. That makes the combination useful for studying dual-pathway endocrine signalling and pulse behaviour. Evidence for the fixed blend is much thinner than the evidence for each component separately.
Component-based; fixed-blend evidence is limited
Research focus
Key research areas
Why researchers pair CJC-1295 No DAC and Ipamorelin
This combined identity brings together a GHRH-related material and a ghrelin-receptor agonist. Separate component studies do not establish evidence for the fixed blend. Published findings concern defined experimental materials and do not establish the identity, quality, safety, efficacy or equivalence of Bear Biotech catalogue material.
- GHRH signalling
- GHS receptor
- Blend evidence limits
Representative primary research
Representative research
No direct primary study of the named blend was located; the links below concern its listed components separately.
- CJC-1295 contextual research ↗ This study concerns DAC-equipped CJC-1295, not the No DAC designation.
- Ipamorelin component research ↗ Original ipamorelin pharmacology study.
Important distinction Component references do not establish the combined formulation.
These sources provide research context only. They do not verify the identity, quality or equivalence of a Bear Biotech catalogue batch; the matched lot-specific batch record remains controlling.
Specifications
Product information
- Material identity
- CJC-1295 (No DAC) + Ipamorelin
- Research category
- Combined GHRH and growth-hormone-secretagogue research materials
- Evidence position
- Component-based; fixed-blend evidence is limited
- Recorded formats
- Staff-prepared solution
- Batch-record basis
- The matched lot-specific record controls identity and analytical claims.
- Intended use
- Controlled laboratory research only.
Research questions
Evidence and identity questions
What is the dual-receptor rationale for studying CJC-1295 No DAC with Ipamorelin?
CJC-1295 (No DAC) + Ipamorelin places GHRH-receptor signalling from the CJC component alongside growth-hormone secretagogue receptor signalling from Ipamorelin. Researchers can then examine how two distinct upstream signals converge on defined pituitary endpoints.
How does omitting the Drug Affinity Complex change the CJC component?
Within CJC-1295 (No DAC) + Ipamorelin, the CJC component lacks the drug-affinity-complex chemistry used to extend albumin association and half-life. It is therefore treated as a short-acting GHRH analogue and must not be conflated with CJC-1295 with DAC.
How much direct evidence exists for the fixed CJC-1295 No DAC and Ipamorelin blend?
Direct evidence for the fixed CJC-1295 (No DAC) + Ipamorelin material is limited. Most scientific context comes from component research, which cannot by itself establish the identity or behaviour of the documented blend.
Batch documentation
Lot-specific records stay connected to the order
Eligible lot-specific documentation may be viewed or requested from the registered Bear Biotech account when available for the applicable order.
Open Bear Biotech accountResearch use only
Controlled laboratory research material
Not for human or veterinary consumption. Administration, dosing and therapeutic guidance are not provided.